



Michigan Cancer Consortium Recommendations for Prostate Cancer Survivorship Care

References

1. Hassouna MM, Heaton JP: Prostate cancer: 8. Urinary incontinence and erectile dysfunction. *CMAJ* 160:78-86, 1999
2. Filocamo MT, Li Marzi V, Del Popolo G, et al: Effectiveness of early pelvic floor rehabilitation treatment for post- prostatectomy incontinence. *Eur Urol* 48:734-8, 2005
3. Grise P, Thurman S: Urinary incontinence following treatment of localized prostate cancer. *Cancer Control* 8:532-9, 2001
4. Van Kampen M, De Weerd W, Van Poppel H, et al: Effect of pelvic-floor re-education on duration and degree of incontinence after radical prostatectomy: a randomised controlled trial. *Lancet* 355:98-102, 2000
5. Moore KN, Schieman S, Ackerman T, et al: Assessing comfort, safety, and patient satisfaction with three commonly used penile compression devices. *Urology* 63:150-4, 2004
6. Aboseif SR, O'Connell HE, Usui A, et al: Collagen injection for intrinsic sphincteric deficiency in men. *J Urol* 155:10-3, 1996
7. Smith DN, Appell RA, Rackley RR, et al: Collagen injection therapy for post-prostatectomy incontinence. *J Urol* 160:364-7, 1998
8. Litwiller SE, Kim KB, Fone PD, et al: Post-prostatectomy incontinence and the artificial urinary sphincter: a long-term study of patient satisfaction and criteria for success. *J Urol* 156:1975-80, 1996
9. Venn SN, Greenwell TJ, Mundy AR: The long-term outcome of artificial urinary sphincters. *J Urol* 164:702-6; discussion 706-7, 2000
10. Stern JA, Clemens JQ, Tiplitsky SI, et al: Long-term results of the bulbourethral sling procedure. *J Urol* 173:1654-6, 2005
11. Comiter CV: The male perineal sling: intermediate-term results. *Neurourol Urodyn* 24:648-53, 2005
12. Zippe CD, Jhaveri FM, Klein EA, et al: Role of Viagra after radical prostatectomy. *Urology* 55:241-5, 2000
13. Meuleman EJ, Mulders PF: Erectile function after radical prostatectomy: a review. *Eur Urol* 43:95-101; discussion 101-2, 2003
14. Urciuoli R, Cantisani TA, Carlini M, et al: Prostaglandin E1 for treatment of erectile dysfunction. *Cochrane Database Syst Rev*:CD001784, 2004
15. Baniel J, Israilov S, Segenreich E, et al: Comparative evaluation of treatments for erectile dysfunction in patients with prostate cancer after radical retropubic prostatectomy. *BJU Int* 88:58-62, 2001
16. Vale J: Erectile dysfunction following radical therapy for prostate cancer. *Radiother Oncol* 57:301-5, 2000
17. Carson CC, Mulcahy JJ, Govier FE: Efficacy, safety and patient satisfaction outcomes of the AMS 700CX inflatable penile prosthesis: results of a long-term multicenter study. AMS 700CX Study Group. *J Urol* 164:376-80, 2000
18. Larson DW, Chrouser K, Young-Fadok T, et al: Rectal complications after modern radiation for prostate cancer: a colorectal surgical challenge. *J Gastrointest Surg* 9:461-6, 2005



Michigan Cancer Consortium Recommendations for Prostate Cancer Survivorship Care

References

19. Loprinzi CL, Barton DL, Carpenter LA, et al: Pilot evaluation of paroxetine for treating hot flashes in men. *Mayo Clin Proc* 79:1247-51, 2004
20. Moraska AR, Atherton PJ, Szydlo DW, et al: Gabapentin for the management of hot flashes in prostate cancer survivors: a longitudinal continuation Study-NCCTG Trial N00CB. *J Support Oncol* 8:128-32, 2010
21. Filshie J, Bolton T, Browne D, et al: Acupuncture and self acupuncture for long-term treatment of vasomotor symptoms in cancer patients--audit and treatment algorithm. *Acupunct Med* 23:171-80, 2005
22. Hammar M, Frisk J, Grimas O, et al: Acupuncture treatment of vasomotor symptoms in men with prostatic carcinoma: a pilot study. *J Urol* 161:853-6, 1999
23. McLeod N, Huynh CC, Rashid P: Osteoporosis from androgen deprivation therapy in prostate cancer treatment. *Aust Fam Physician* 35:243-5, 2006
24. Diamond TH, Bucci J, Kersley JH, et al: Osteoporosis and spinal fractures in men with prostate cancer: risk factors and effects of androgen deprivation therapy. *J Urol* 172:529-32, 2004
25. Lipton A, Small E, Saad F, et al: The new bisphosphonate, Zometa (zoledronic acid), decreases skeletal complications in both osteolytic and osteoblastic lesions: a comparison to pamidronate. *Cancer Invest* 20 Suppl 2:45-54, 2002